• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经济评估中基于效用的健康结果测量的公平性考量:一种调整算法。

Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm.

作者信息

Gafni A, Birch S

机构信息

Department of Clinical Epidemiology and Biostatics, McMaster University, Hamilton, Ontario, Canada.

出版信息

J Health Econ. 1991 Oct;10(3):329-42. doi: 10.1016/0167-6296(91)90033-j.

DOI:10.1016/0167-6296(91)90033-j
PMID:10114569
Abstract

In this paper we consider whether methods currently used to measure utility of health outcomes are consistent with the equity criteria adopted by researchers. We show that unless the chosen equity criterion is incorporated in the design of the measurement instrument, the derived health state utilities are inconsistent with the equity criterion (except under special circumstances). Adjustment algorithms are derived, based on the axioms of von Neumann-Morgenstern utility theory, which take account of difference equity criteria currently adopted in the literature. The proposed approach is based on simple lottery questions of the type already used widely in empirical studies.

摘要

在本文中,我们探讨当前用于衡量健康结果效用的方法是否与研究人员采用的公平标准相一致。我们表明,除非在测量工具的设计中纳入所选的公平标准,否则得出的健康状态效用将与公平标准不一致(特殊情况除外)。基于冯·诺依曼-摩根斯坦效用理论的公理推导了调整算法,该算法考虑了文献中目前采用的不同公平标准。所提出的方法基于实证研究中已广泛使用的简单彩票问题类型。

相似文献

1
Equity considerations in utility-based measures of health outcomes in economic appraisals: an adjustment algorithm.经济评估中基于效用的健康结果测量的公平性考量:一种调整算法。
J Health Econ. 1991 Oct;10(3):329-42. doi: 10.1016/0167-6296(91)90033-j.
2
Assigning values to intermediate health states for cost-utility analysis: theory and practice.为成本效用分析为中间健康状态赋值:理论与实践
Med Decis Making. 1996 Oct-Dec;16(4):376-85. doi: 10.1177/0272989X9601600408.
3
Health utility indices and equity considerations.健康效用指数与公平性考量。
J Health Econ. 1997 Feb;16(1):65-91. doi: 10.1016/s0167-6296(96)00508-5.
4
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?成本效益/效用分析。当前的决策规则能引领我们实现目标吗?
J Health Econ. 1992 Oct;11(3):279-96. doi: 10.1016/0167-6296(92)90004-k.
5
Implications of basing health-care resource allocations on cost-utility analysis in the presence of externalities.存在外部性时基于成本效用分析进行医疗保健资源分配的影响。
J Health Econ. 1992 Oct;11(3):259-77. doi: 10.1016/0167-6296(92)90003-j.
6
Discounting in the economic evaluation of health care interventions.医疗保健干预措施经济评估中的贴现
Med Care. 1993 May;31(5):403-18. doi: 10.1097/00005650-199305000-00003.
7
Economic foundations of cost-effectiveness analysis.成本效益分析的经济基础。
J Health Econ. 1997 Feb;16(1):1-31. doi: 10.1016/s0167-6296(96)00506-1.
8
Much ado about two: reconsidering retransformation and the two-part model in health econometrics.小题大做:重新审视健康计量经济学中的再转换和两部分模型。
J Health Econ. 1998 Jun;17(3):247-81. doi: 10.1016/s0167-6296(98)00030-7.
9
Cost-effectiveness analysis in heart disease, Part I: General principles.心脏病的成本效益分析,第一部分:一般原则。
Prog Cardiovasc Dis. 1994 Nov-Dec;37(3):161-84. doi: 10.1016/s0033-0620(05)80041-6.
10
Modelling programme costs in economic evaluation.经济评估中的项目成本建模
J Health Econ. 1996 Feb;15(1):115-25. doi: 10.1016/0167-6296(95)00016-x.

引用本文的文献

1
Comparable worth of life for all? Conducting and disseminating health economic evaluations for refugees in Germany.所有人的生命都有同等价值吗?在德国对难民进行和传播卫生经济评估。
Global Health. 2022 May 12;18(1):48. doi: 10.1186/s12992-022-00845-1.
2
Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.将公平性问题纳入成本效益分析中:系统文献回顾。
Pharmacoeconomics. 2022 Jan;40(1):45-64. doi: 10.1007/s40273-021-01094-7. Epub 2021 Oct 29.
3
Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?
出于资源分配目的,癌症药物拥有单独的报销审查流程是否有经济方面的合理性?
Pharmacoeconomics. 2015 Mar;33(3):235-41. doi: 10.1007/s40273-014-0238-7.
4
Recommendations for increasing the use of HIV/AIDS resource allocation models.提高 HIV/AIDS 资源分配模型使用的建议。
BMC Public Health. 2009 Nov 18;9 Suppl 1(Suppl 1):S8. doi: 10.1186/1471-2458-9-S1-S8.
5
Resource allocation within Australian indigenous communities: a program for implementing vertical equity.澳大利亚原住民社区的资源分配:一项实施垂直公平的计划。
Health Care Anal. 2000;8(3):217-33. doi: 10.1023/A:1009458714162.
6
Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.加拿大药品经济评估指南。加拿大药物经济学协作研讨会。
Pharmacoeconomics. 1996 Jun;9(6):535-59. doi: 10.2165/00019053-199609060-00008.
7
Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).药物干预经济评估中基于偏好的结局指标:质量调整生命年(QALYs)与健康年当量(HYEs)。
Pharmacoeconomics. 1992 May;1(5):338-45. doi: 10.2165/00019053-199201050-00005.
8
Alternatives to the QALY measure for economic evaluations.
Support Care Cancer. 1997 Mar;5(2):105-11. doi: 10.1007/BF01262566.
9
Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.新技术采用指南:开支无节制增长的根源及应对之策
CMAJ. 1993 Mar 15;148(6):913-7.
10
The standard gamble method: what is being measured and how it is interpreted.标准博弈法:所测量的内容及其解释方式。
Health Serv Res. 1994 Jun;29(2):207-24.